{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:10:25Z","timestamp":1791497425687,"version":"4.3.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2020,5,18]]},"abstract":"\n Background<\/jats:title>\n \n Identification of patients with stable coronary heart disease who are at significant residual risk could be helpful for targeted prevention. Our aim was to determine the prognostic value of the recently introduced ceramide\u2010 and phospholipid\u2010based risk score, the Cardiovascular Event Risk Test (\n CERT<\/jats:styled-content>\n 2), in patients with stable coronary heart disease on optimal medical therapy and to identify biological processes that contribute to the\n CERT<\/jats:styled-content>\n 2 score.\n <\/jats:p>\n <\/jats:sec>\n \n Methods and Results<\/jats:title>\n \n Plasma samples (n=11\u00a0222) obtained from the\n STABILITY<\/jats:styled-content>\n (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial were analyzed using a tandem liquid chromatography\u2010mass spectrometry method.\n STABILITY<\/jats:styled-content>\n was a trial in patients with stable coronary heart disease randomized to the lipoprotein\u2010associated phospholipase A2 inhibitor darapladib or placebo on optimized medical therapy at baseline, with a median follow\u2010up of 3.7\u00a0years. Hazard ratios per\n SD<\/jats:styled-content>\n for the\n CERT<\/jats:styled-content>\n 2 risk score were 1.32 (95% CI, 1.25\u20131.39) for major adverse cardiovascular event, 1.47 (95% CI, 1.35\u20131.59) for cardiovascular death, 1.32 (95% CI, 1.16\u20131.49) for stroke, 1.23 (95% CI, 1.14\u20131.33) for myocardial infarction, and 1.56 (95% CI, 1.39\u20131.76) for hospitalization due to heart failure, when adjusted for traditional cardiovascular risk factors.\n CERT<\/jats:styled-content>\n 2 showed correlation (\n P<\/jats:italic>\n <0.001,\n r<\/jats:italic>\n >0.2) with inflammatory markers high\u2010sensitivity C\u2010reactive protein, interleukin 6, the heart failure marker N\u2010terminal pro\u2010B\u2010type natriuretic peptide, and low\u2010density lipoprotein cholesterol. After also adjusting for levels of other prognostic biomarkers, the\n CERT<\/jats:styled-content>\n 2 score was still independently related to the risk of cardiovascular death but not to nonfatal events.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The\n CERT<\/jats:styled-content>\n 2 risk score can detect residual risk in patients with stable coronary heart disease and is associated with biomarkers indicating inflammation, myocardial necrosis, myocardial dysfunction, renal dysfunction, and dyslipidemia.\n <\/jats:p>\n <\/jats:sec>\n \n REGISTRATION<\/jats:title>\n \n URL<\/jats:styled-content>\n :\n https:\/\/www.clini\u200bcaltr\u200bials.gov<\/jats:ext-link>\n . Unique identifier:\n NCT<\/jats:styled-content>\n 00799903.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1161\/jaha.119.015258","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T05:00:15Z","timestamp":1588827615000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":65,"title":["Prediction of Residual Risk by Ceramide\u2010Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy"],"prefix":"10.1161","volume":"9","author":[{"given":"Mika","family":"Hilvo","sequence":"first","affiliation":[{"name":"Zora Biosciences Oy Espoo Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Uppsala University Uppsala Sweden"},{"name":"Uppsala Clinical Research Center Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatevik","family":"Ghukasyan Lakic","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Held","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Uppsala University Uppsala Sweden"},{"name":"Uppsala Clinical Research Center Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimple","family":"Kauhanen","sequence":"additional","affiliation":[{"name":"Zora Biosciences Oy Espoo Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Jylh\u00e4","sequence":"additional","affiliation":[{"name":"Zora Biosciences Oy Espoo Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lindb\u00e4ck","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Siegbahn","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Uppsala University Uppsala Sweden"},{"name":"Uppsala Clinical Research Center Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[{"name":"Medical Center Duke University Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum M\u00fcnchen Technische Universit\u00e4t M\u00fcnchen M\u00fcnchen Germany and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance Munich Germany"},{"name":"Institute of Epidemiology and Medical Biometry University of Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A. H.","family":"Stewart","sequence":"additional","affiliation":[{"name":"N Green Lane Cardiovascular Service Auckland City Hospital and University of Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"White","sequence":"additional","affiliation":[{"name":"N Green Lane Cardiovascular Service Auckland City Hospital and University of Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reijo","family":"Laaksonen","sequence":"additional","affiliation":[{"name":"Zora Biosciences Oy Espoo Finland"},{"name":"Finnish Cardiovascular Research Center University of Tampere Finland"},{"name":"Finnish Clinical Biobank Tampere Tampere University Hospital Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the STABILITY Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw148"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.307497"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz387"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152012800228661"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13475"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00281.x"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.04.002"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4590-6"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy319"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315878"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.06.030"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005077"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-016-9425-z"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"1\u201326","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell FE","year":"2015","unstructured":"Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. New York, NY: Springer; 2015:1\u201326\u20131\u201327."},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.359950"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812792"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012415"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.119.015258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T07:58:10Z","timestamp":1715587090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.119.015258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,18]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,5,18]]}},"alternative-id":["10.1161\/JAHA.119.015258"],"URL":"https:\/\/doi.org\/10.1161\/jaha.119.015258","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,18]]},"assertion":[{"value":"2019-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e015258"}}